(Z)-SMI-4a 是一种选择性的，细胞可渗透的且具有 ATP 竞争性的Pim-1抑制剂，IC50为 24 μM，Ki为 0.6 μM。它还抑制Pim-2，IC50为 100 μM，具有抗癌活性。

(Z)-SMI-4a is a selective ATP-competitive Pim-1 kinase inhibitor with an IC50 of 21 nM.

口服SMI-4a后1小时,与对照组小鼠肿瘤相比,p70 S6K磷酸化减少,而总的p70 S6K表达不变.每天60 mg/kg SMI-4a处理两次,明显降低肿瘤尺寸,且具有良好的耐受性.

5 μM SMI-4a抑制胰腺癌和白血病细胞生长。SMI-4a降低前列腺和造血细胞中Pim靶点的磷酸化。SMI-4a引起细胞周期停滞并逆转Pim-1的抗凋亡活性。SMI-4a是Pim1的ATP竞争性抑制剂,IC50为17 nM。SMI-4a显示Pim1对一组激酶具有高选择性。SMI-4a抑制已知底物即翻译阻遏物4E-BP1的Pim-1的体外磷酸化。SMI-4a增加细胞核中p27Kip1的量。SMI-4a处理诱导MAPK通路上调。SMI-4a处理pre-T-LBL,抑制mTOR通路。

Scintillation Proximity Assay: Methyltransferase activity assays are performed by monitoring the incorporation of tritiumlabeled methyl group from S-adenosylmethionine (3H-SAM) to biotinylated peptide substrates using Scintillation Proximity Assay (SPA) for PRC2-EZH2 trimeric complex (EZH2:EED:SUZ12), PRC2-EZH1 pentameric complex (EZH1:EED:SUZ12:RBBP4:AEBP2), SETD7, G9a, GLP, SETDB1, SETD8, SUV420H1, SUV420H2, SUV39H2, MLL1 tetrameric complex (MLL:WDR5:RbBP5:ASH2L), PRMT1, PRMT3, PRMT5-MEP50 complex and SMYD2. The reaction buffer for SMYD2 and SMYD3 is 50 mM Tris pH 9.0, 5 mM DTT, 0.01% TritonX-100; for G9a, GLP and SUV39H2 is 25 mM potassium phosphate pH 8.0, 1 mM EDTA, 2 mM MgCl2 and 0.01% Triton X-100; and for other HMTs 20 mM Tris pH 8.0, 5 mM DTT, 0.01% TritonX-100. To stop the enzymatic reactions, 10 μL of 7.5 M guanidine hydrochloride is added, followed by 180 μL of buffer, mixed and transferred to a 384-well FlashPlate. After mixing, the reaction mixtures are incubated and the CPM counts are measured using Topcount plate reader. The CPM counts in the absence of compound for each data set are defined as 100% activity. In the absence of the enzyme, the CPM counts in each data set are defined as background (0%). IC50 values are determined using compound concentrations ranging from 100 nM to 100 μM. The IC50 values are determined using SigmaPlot software. EZH2-Y641F assays are performed using 30 nM of enzyme in 20 mM Tris pH 8, 5 mM DTT, 0.01% Triton X-100, 5 μM SAM and 1 μM of H3 (1-24) peptide (same as for the wild-type PRC2-EZH2 complex). For DNMT1, the assay is performed using hemimethylated dsDNA as a substrate. The dsDNA substrate is prepared by annealing two complementary strands (biotintlated forward strand: BGAGCCCGTAAGCCCGTTCAGGTCG and reverse strand: CGACCTGAACGGGCTTACGGGCTC), synthesized by Eurofins MWG Operon. Reaction buffer is 20 mM Tris-HCl, pH 8.0, 5 mM DTT, 0.01% Triton X-100.Methyltransferase activity assays for DOT1L is performed using Filter-plates. Reaction mixtures in 20 mM Tris-HCl, pH 8.0, 5 mM DTT, 2 mM MgCl2 and 0.01% Triton X-100 are incubated at room temperature for 1h, 100 μL 10% TCA is added, mixed and transferred to filter-plate. Plates are centrifuged at 2000 rpm for 2 min followed by 2 additional 10% TCA wash and one ethanol wash (180 μL) followed by centrifugation. Plates are dried and 100 μL MicroO is added and centrifuged. 70 μL MicroO is added and CPM are measured using Topcount plate reader.

438190-29-5

C11H6F3NO2S

273.23

SMI-4a;TCS PIM-1 4a

Ethanol:27.3 mg/mL (100 mM)
DMSO:27.3 mg/mL (100 mM)
Powder: -20°C for 3 years
In solvent: -80°C for 2 years